Carl Laflamme

Research Associate

SGC Neuro

During his postdoctoral work at The Neuro, Carl studied the major Amyotrophic Lateral Sclerosis disease gene C9ORF72. Through an antibody validation pipeline that he developed, Carl characterized all known C9ORF72 commercial antibodies and found that the most cited antibody does not recognize the protein in any application, but had been cited in dozens of papers cited thousands of times. Carl and Peter McPherson are further developing the pipeline as a technology solution, along with a sustainable business model, to address the antibody liability crisis. The technology platform, called the NeuroSGC Antibody Characterization Platform, is now being formally implemented at The Neuro through the creation of an Antibody Characterization Group. This group functions in partnership with ten leading antibody/KO cell manufacturers who are distinguished by a commitment to reagent quality and contribute significant cash and in-kind resources to the initiative.

Publicatons CLaflamme

Opinion: Independent third-party entities as a model for validation of commercial antibodies.
Laflamme C, Edwards AM, Bandrowski AE, McPherson PS
N Biotechnol. 2021 65:1-8. doi: 10.1016/j.nbt.2021.07.001
PMID: 34246180

Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72.
Laflamme C, McKeever PM, Kumar R, Schwartz J, Kolahdouzan M, Chen CX, You Z, Benaliouad F, Gileadi O, McBride HM, Durcan TM, Edwards AM, Healy LM, Robertson J, McPherson PS
Elife. 2019 8:. doi: 10.7554/eLife.48363
PMID: 31612854

2024

A guide to selecting high-performing antibodies for Rab1A and Rab1B for use in Western Blot, immunoprecipitation and immunofluorescence.
Ruíz Moleón V, Fotouhi M, Ayoubi R, González Bolívar S, Southern K, McPherson PS, Laflamme C
F1000Res. 17.05.2024 12:1578. doi: 10.12688/f1000research.143928.2
PMID: 38559361

The identification of high-performing antibodies for TDP-43 for use in Western Blot, immunoprecipitation and immunofluorescence.
Worrall D, Ayoubi R, Fotouhi M, Southern K, McPherson PS, Laflamme C
F1000Res. 17.05.2024 12:277. doi: 10.12688/f1000research.131852.2
PMID: 37359785

2023

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications.
Ayoubi R, Ryan J, Biddle MS, Alshafie W, Fotouhi M, Bolivar SG, Ruiz Moleon V, Eckmann P, Worrall D, McDowell I, Southern K, Reintsch W, Durcan TM, Brown C, Bandrowski A, Virk H, Edwards AM, McPherson P, Laflamme C
Elife. 23.11.2023 12:. doi: 10.7554/eLife.91645
PMID: 37995198

The identification of high-performing antibodies for transmembrane protein 106B (TMEM106B) for use in Western blot, immunoprecipitation, and immunofluorescence.
Ayoubi R, Fotouhi M, Southern K, Bhajiawala R, Fanti R, Prinos P, McPherson PS, Laflamme C
F1000Res. 07.08.2023 12:308. doi: 10.12688/f1000research.131333.1
PMID: 37545650

2022

Identification of highly specific antibodies for Serine/threonine-protein kinase TBK1 for use in immunoblot, immunoprecipitation and immunofluorescence.
Alshafie W, Fotouhi M, Shlaifer I, Ayoubi R, Edwards AM, Durcan TM, McPherson PS, Laflamme C
F1000Res. 07.12.2022 11:977. doi: 10.12688/f1000research.124632.2
PMID: 36415206

2021

Opinion: Independent third-party entities as a model for validation of commercial antibodies.
Laflamme C, Edwards AM, Bandrowski AE, McPherson PS
N Biotechnol. 07.07.2021 65:1-8. doi: 10.1016/j.nbt.2021.07.001
PMID: 34246180

2019

Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72.
Laflamme C, McKeever PM, Kumar R, Schwartz J, Kolahdouzan M, Chen CX, You Z, Benaliouad F, Gileadi O, McBride HM, Durcan TM, Edwards AM, Healy LM, Robertson J, McPherson PS
Elife. 15.10.2019 8:. doi: 10.7554/eLife.48363
PMID: 31612854

glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03